L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin.
COMT-inhibitors
Dopamine receptor agonists
History of L-DOPA-therapy
Levodopa
Levodopa combination therapies
Monoamine oxidase inhibitors
Journal
Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
27
06
2023
accepted:
24
08
2023
medline:
15
11
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
Dopamine was initially considered as a mere intermediate in the noradrenaline synthesis but was then found to be a neurotransmitter. Its depletion resulted in characteristic symptoms in experimental studies and could be antagonized by DOPA (3,4-dihydroxyphenylalanin), suggesting a similarity to the human disorder Parkinson´s disease (PD) and a therapeutic potential which was successfully exploited from the 1970s on. This was due to the pioneering work of Arvid Carlsson and clinicians around the world who first worked on the breakthrough of L-DOPA therapy and then on its amendment and modification and on alternative therapies for PD patients. All these developments led to the establishment of PD therapy as we know it today. It is characterized by the availability of many different compounds which are mostly employed in combination and by different methods: orally, intravenously, transdermally, subcutaneously, or duodenally. Here, we present without claim of completeness some personal reflections about causal drug developments for PD patients and reflect on some personal interactions with leading clinicians and basic researchers who cooperated with us. Such interactions are crucial for the creation, sometimes serendipitously, of fresh ideas and to further develop existing concepts to make therapeutical progress.
Identifiants
pubmed: 37796288
doi: 10.1007/s00702-023-02692-9
pii: 10.1007/s00702-023-02692-9
pmc: PMC10645634
doi:
Substances chimiques
Levodopa
46627O600J
Antiparkinson Agents
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1323-1335Informations de copyright
© 2023. The Author(s).
Références
Lancet. 1977 Feb 26;1(8009):439-43
pubmed: 65560
Wien Klin Wochenschr. 1971 Apr 2;83(13):221-7
pubmed: 4254333
Wien Klin Wochenschr. 1961 Nov 10;73:787-8
pubmed: 13869404
Pharmacol Rev. 1959 Jun;11(2, Part 2):490-3
pubmed: 13667431
J Neural Transm (Vienna). 2019 Apr;126(4):449-454
pubmed: 30805732
Drugs Aging. 2004;21(11):687-709
pubmed: 15323576
Nature. 1957 Aug 3;180(4579):244-5
pubmed: 13451690
Chem Ber. 1972;105(4):1168-73
pubmed: 4661049
Psychopharmacologia. 1967;10(4):316-23
pubmed: 5627343
J Neural Transm Suppl. 2006;(70):9-15
pubmed: 17017502
Experientia. 1959 Jan 15;15(1):10-1
pubmed: 13619664
Wurzbg Medizinhist Mitt. 2003;22:215-34
pubmed: 15641199
N Engl J Med. 1969 Feb 13;280(7):337-45
pubmed: 4178641
Science. 1961 May 26;133(3465):1706-7
pubmed: 13686753
Eur J Pharmacol. 1991 Apr 25;206(4):297-300
pubmed: 1717296
Ann Neurol. 1993 May;33(5):507-11
pubmed: 8098931
Wien Klin Wochenschr. 1969 Sep 26;81(39):677-9
pubmed: 5344299
Z Klin Med. 1953;152(1-2):46-57
pubmed: 13147345
Lancet. 1974 Dec 7;2(7893):1355-6
pubmed: 4143315
Neuropharmacology. 2002 Dec;43(7):1110-8
pubmed: 12504917
Neurology. 1992 Jun;42(6):1241-3
pubmed: 1351273
Experientia. 1959 Oct 15;15:382-4
pubmed: 13799996
Acta Med Acad Sci Hung. 1967;23(3):289-95
pubmed: 6056555
Neurosci Lett. 1983 Feb 21;35(2):185-9
pubmed: 6222273
Mod Probl Pharmacopsychiatry. 1983;19:170-6
pubmed: 6408405
Nature. 1957 Nov 30;180(4596):1200
pubmed: 13483658
Trans Am Neurol Assoc. 1951;56:251-3
pubmed: 14913646
Adv Neurol. 1987;45:573-6
pubmed: 3825735
Arch Int Pharmacodyn Ther. 1965 May;155(1):154-64
pubmed: 4378644
Nat Clin Pract Neurol. 2007 Jun;3(6):E1
pubmed: 17549055
Med Secoli. 1991;3(2-3):191-206
pubmed: 11640121
Brain. 1984 Jun;107 ( Pt 2):487-506
pubmed: 6722513
Klin Wochenschr. 1960 Jan 15;38:57-62
pubmed: 14441534
Lancet. 1988 Feb 20;1(8582):403-6
pubmed: 2893200
Nature. 1967 Aug 19;215(5103):852-3
pubmed: 6049735
J Neural Transm Park Dis Dement Sect. 1991;3(3):151-201
pubmed: 1683537
Med Welt. 1973 Aug 24;24(33):1278-82
pubmed: 4764443
Ther Clin Risk Manag. 2018 Sep 18;14:1737-1745
pubmed: 30271159
Nature. 1957 Nov 23;180(4595):1127-8
pubmed: 13483629
Lancet. 1979 May 5;1(8123):954-6
pubmed: 87620
Biochem Pharmacol. 1968 Jul;17(7):1285-97
pubmed: 5659776
Mov Disord. 2015 Jan;30(1):19-36
pubmed: 25488030
J Neural Transm (Vienna). 2021 Feb;128(2):127-169
pubmed: 33624170
JAMA. 1969 May 19;208(7):1168-70
pubmed: 5818715
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804
pubmed: 12388666
Biochem J. 1928;22(4):968-79
pubmed: 16744124
Arch Psychiatr Nervenkr (1970). 1967 Aug 8;210(1):29-35
pubmed: 4292871
Science. 1958 Feb 28;127(3296):471
pubmed: 13529006
Lancet. 1987 Apr 11;1(8537):871
pubmed: 2882282
Pharmacol Rev. 1966 Jun;18(2):925-64
pubmed: 5328389
Amino Acids. 2002;23(1-3):65-70
pubmed: 12373520
BMJ. 1998 Feb 28;316(7132):641
pubmed: 9522772
Ann Neurol. 1986 Aug;20(2):262-5
pubmed: 3752968
Med Monatsschr. 1971 Oct;25(10):472-9
pubmed: 5122447
Science. 1957 Aug 30;126(3270):400-1
pubmed: 13467217
Lancet. 1986 Mar 1;1(8479):467-70
pubmed: 2869209
Eur J Pharmacol. 1989 Aug 3;166(3):589-90
pubmed: 2680528
Expert Rev Clin Pharmacol. 2023 Feb;16(2):101-107
pubmed: 36726198
Experientia. 1962 Sep 15;18:411-2
pubmed: 14017032
Biochim Biophys Acta. 1959 Apr;32:586-7
pubmed: 14441532
Neurosci Lett. 1980 Dec;20(3):379-82
pubmed: 6108541
Acta Physiol Scand. 1958 Dec 15;44(3-4):273-92
pubmed: 13617023
Eur J Pharmacol. 1976 Apr;36(2):373-83
pubmed: 945166
Acta Physiol Scand. 1959 Dec 12;47:350-61
pubmed: 13799995
Nature. 1964 Mar 21;201:1228-9
pubmed: 14151382
Clin Neuropharmacol. 2003 Jul-Aug;26(4):213-7
pubmed: 12897643
Klin Wochenschr. 1960 Feb 1;38:120-3
pubmed: 13815400
Parkinsonism Relat Disord. 2000 Jan;6(1):3-6
pubmed: 18591145
Ann Neurol. 1988 Jul;24(1):87-9
pubmed: 3415201
Experientia. 1957 Jan 15;13(1):9-13
pubmed: 13404987
J Pharmacol Exp Ther. 1968 May;161(1):14-20
pubmed: 5648492
Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):141-7
pubmed: 12769623
CNS Drugs. 2004;18(4):251-67
pubmed: 15015905
J Physiol. 1910 Oct 11;41(1-2):19-59
pubmed: 16993040
Clin Neuropharmacol. 2006 Mar-Apr;29(2):80-6
pubmed: 16614540
J Neural Transm. 1975;36(3-4):303-26
pubmed: 1172524
Biochem J. 1937 Dec;31(12):2187-96
pubmed: 16746563
J Neurol Sci. 1971 Oct;14(2):193-7
pubmed: 5112212
Neurology. 1960 May;10:446-51
pubmed: 13796577
Nervenarzt. 1963 Aug;34:373-4
pubmed: 14163215
Arzneimittelforschung. 1964 Jun;14:SUPPL:599-601
pubmed: 14253979